Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have poorer outcomes compared to other breast cancers, suggesting the need for improved treatments. One new therapy being investigated at Moffitt Cancer Center involves oncolytic viruses, which infect and kill cancer cells.
In a new study published in the journal Nature Medicine, the researchers, led by Hatem Soliman, MD, share results from a phase 2 clinical trial of the oncolytic virus talimogene laherparepvec (TVEC) combined with standard chemotherapy in patients with early-stage triple-negative breast cancer.
Patients with triple-negative breast cancer lack expression of the estrogen and progesterone receptors and have little to no expression of the protein HER2. As a result, hormone therapy and medicines that target HER2 protein receptors are not effective against this type of cancer. Standard therapy for early-stage triple-negative breast cancer has been cytotoxic chemotherapy with the recent addition of pembrolizumab. However, this approach is associated with significant side effects. Many studies have shown that patients who have higher levels of immune cells within their tumours tend to have better responses to therapy. These observations suggest that agents that stimulate the immune system may be beneficial in triple-negative breast cancer.
TVEC is a modified herpes simplex 1 virus that includes coding sequences for the protein GM-CSF, which can stimulate the immune system. It is injected directly into the tumour and undergoes replication within the tumour cells, resulting in the breakdown of the tumour cell and the production of tumour-derived antigens. Immune cells can recognise the antigens, infiltrate the tumour and target the cancer cells for destruction. In addition, GM-CSF made by the virus acts as a beacon to help recruit immune cells to the tumour.
TVEC is approved to treat advanced, late-stage melanoma. Moffitt researchers wanted to assess whether the oncolytic virus also could be effective in combination with standard chemotherapy when given to triple-negative breast cancer patients before surgery. In a phase 2 trial of 37 patients, 45.9% achieved a response, 89% of the patients remained disease free two years post-treatment, and no recurrences occurred in patients who achieved strong responses. The safety profile did not differ significantly from what was expected of standard chemotherapy, except for higher levels of low-grade fevers, chills, headaches and injection site pain.
The researchers also analyzed levels of immune biomarkers and assessed whether these biomarkers correlated with patient responses. They discovered that most tumour samples had higher levels of tumour-fighting T cells and activation of immune signalling pathways during the first six weeks of treatment. Patients who had better responses to therapy had higher levels of CD8 T cells at week six than patients who did not respond as well to therapy. These observations suggest that activating an immune response earlier may lead to better outcomes in triple-negative breast cancer patients.
“Our results demonstrate that TVEC, when added to systemic chemotherapy, may increase responses in high-risk, early-stage triple-negative breast cancer. There is evidence of robust immune activation within the tumour, and additional investigation of TVEC in combination with current chemoimmunotherapy for triple-negative breast cancer is warranted,” said Soliman, lead study author, medical director of Moffitt’s Clinical Trials Office and senior member of Moffitt’s Breast Oncology Department.